drugset / Trial / NCT03354273

An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)

NCT03354273

NaSingle-groupOpen-labelDiagnostic

Summary

This is a Phase 3, prospective, open-label, international, multicentre study of Flurpiridaz (18F) Injection for PET MPI in patients referred for ICA because of suspected CAD.

Timeline

Start
2018-06-05
Primary completion
2022-05-05
Completion
2022-05-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Flurpiridaz Diagnostic / imaging agent 520 mbq Intravenous
Background Adenosine Small molecule Intravenous
Background Dipyridamole Other / unclassified Intravenous
Background Regadenoson Diagnostic / imaging agent Intravenous